Vera Heuer

Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial

Sylvie Lorenzen, Thorsten Oliver Götze, Peter Thuss‐Patience et al. · Journal of Clinical Oncology · 2023 · 195 citations

Medicine, Oncology, Perioperative Medicine +17

Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK.

Salah-Eddin Al-Batran, Sylvie Lorenzen, Peter Thuss‐Patience et al. · Journal of Clinical Oncology · 2022 · 96 citations

Medicine, Oncology, Surgery +16

1429P Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: Results from the DANTE trial of the German Gastric Group at the AIO and SAKK

S-E. Al-Batran, Sylvie Lorenzen, Nils Homann et al. · Annals of Oncology · 2021 · 31 citations

Medicine, Oncology, Surgery +13

Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.

Salah‐Eddin Al‐Batran, Claudia Pauligk, Ralf‐Dieter Hofheinz et al. · Journal of Clinical Oncology · 2019 · 23 citations

Medicine, Oncology, Pharmacology +17

A randomized, open-label, phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF-S633/DANTE trial, a trial of AIO in collaboration with SAKK.

Salah-Eddin Al-Batran, Sylvie Lorenzen, Peter Thuss‐Patience et al. · Journal of Clinical Oncology · 2023 · 13 citations

Medicine, Oncology, Pharmacology +14